Trial Profile
Le20: clinical and pathologic studies in non-Hodgkin's lymphoma patients receiving antibody treatment.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2012
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
- 01 Jun 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Dec 2009 Planned number of patients (500) added as reported by ClinicalTrials.gov.